Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion type Assertion NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_head.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion description "[Despite patients with FIP1-like-1-platelet-derived growth factor alpha (FIP1L1-PDGFRA) associated HES (myeloid neoplasms associated with PDGFRA rearrangement) have been shown to respond to low-dose imatinib with a complete and durable hematological and cytogenetic remission, influences of imatinib on clinical manifestations related to hypereosinophilia heart involvement are variable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_provenance.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion evidence source_evidence_literature NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_provenance.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion SIO_000772 19096755 NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_provenance.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion wasDerivedFrom befree-2016 NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_provenance.
- NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_assertion wasGeneratedBy ECO_0000203 NP710339.RAf9dnLQRxZhftCBCz5lVn2SLUuvuLMO18xhe-ntCRDJA130_provenance.